Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors

PURPOSE: The relapse rate after primary retroperitoneal lymph node dissection (RPLND) for patients with pathologic stage (PS) IIA nonseminomatous germ cell tumors (NSGCTs) is 10%-20% but increases to ≥ 50% for PS IIB disease. We report our experience with 2 cycles of adjuvant etoposide plus cisplati...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Oncol
Egile Nagusiak: McHugh, Deaglan J., Funt, Samuel A., Silber, Deborah, Knezevic, Andrea, Patil, Sujata, O’Donnell, Devon, Tsai, Stephanie, Reuter, Victor E., Sheinfeld, Joel, Carver, Brett S., Motzer, Robert J., Bajorin, Dean F., Bosl, George J., Feldman, Darren R.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2020
Gaiak:
ORIGINAL REPORTS
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7164484/
https://ncbi.nlm.nih.gov/pubmed/32109195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.02712
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak